How Does BIOGEN INC. Sit in Its SEC Industry Classification?
BIOGEN INC. files under SEC standard industrial classification 2836, Biological Products, (No Diagnostic Substances). Among the 87 companies Swoopr covers under SIC 2836, its latest reported revenue of $9.9 billion ranks 3rd. The comparison uses each company's own latest fiscal year, which can differ by up to a year across the group.
| Measure | BIOGEN INC. (FY2025) | Peer reference |
|---|---|---|
| Revenue | $9.9 billion | 3rd of 87 |
| Revenue growth | +2.2% | +10.0% (median of 3 peers with a quarter to four times its revenue) |
Companies of similar size in the same classification: GILEAD SCIENCES, INC. ($29.4 billion), NEUROCRINE BIOSCIENCES INC ($2.9 billion), AMGEN INC ($36.8 billion), EXELIXIS, INC. ($2.3 billion), Moderna, Inc. ($1.9 billion).
A classification code groups companies by how they describe their main business to the SEC, so two companies with the same code can still differ in customers, geography and cost structure. Treat the comparison as a starting point for the questions below.
Where value can be captured
The health-care chain may include research, clinical development, regulators, manufacturing, distributors, providers, payers, pharmacies, and patients. Economic power depends on clinical differentiation, intellectual property, reimbursement, and access to distribution.
For Biogen, name suppliers, channels, customers and infrastructure dependencies only when a reliable source establishes the relationship. The goal is to show where the company sits, what it depends on, and where bargaining power resides.
Industry drivers
- Procedure Or Patient Volume: connect this driver to a disclosed KPI and to the financial statement line it influences.
- New Product Adoption: connect this driver to a disclosed KPI and to the financial statement line it influences.
- Pricing And Reimbursement: connect this driver to a disclosed KPI and to the financial statement line it influences.
- Clinical Pipeline Progress: connect this driver to a disclosed KPI and to the financial statement line it influences.
- Prescription Volume: connect this driver to a disclosed KPI and to the financial statement line it influences.
- Installed Base: connect this driver to a disclosed KPI and to the financial statement line it influences.
- Service Utilization: connect this driver to a disclosed KPI and to the financial statement line it influences.
- Research And Development Productivity: connect this driver to a disclosed KPI and to the financial statement line it influences.
Macro connections
- Health-Care Utilization: document the transmission mechanism rather than assuming correlation.
- Employment And Insurance Coverage: document the transmission mechanism rather than assuming correlation.
- Government Reimbursement Policy: document the transmission mechanism rather than assuming correlation.
- Interest Rates For Provider Capital Budgets: document the transmission mechanism rather than assuming correlation.
- Demographics: document the transmission mechanism rather than assuming correlation.
- Biopharma Research Spending: document the transmission mechanism rather than assuming correlation.
Peer map
A starting peer group from the current S&P 500 classification is AbbVie, Amgen, Gilead Sciences, Incyte, Moderna, Regeneron Pharmaceuticals. Some may be adjacent rather than direct competitors. The latest Biogen filing and credible industry sources should refine the map.
Questions for the supply-chain map
- Which inputs are scarce, concentrated, regulated, or difficult to substitute?
- Which layer has the highest switching costs?
- Where can capacity expand quickly, and where does it take years?
- Which participants bear inventory, credit, commodity, or utilization risk?
- Is Biogen's advantage located in intellectual property, physical assets, licenses, distribution, brand, data, or customer integration?
- Which dependency could become a bottleneck under stress?
References
The evergreen analysis above is anchored to verified index metadata and a filing-first research workflow. Time-sensitive financial figures are refreshed from the latest primary filings.
- S&P Dow Jones Indices: S&P 500
- SEC EDGAR company filings for Biogen
- SEC submissions JSON for CIK 875045
Source-review rule: Check any statement about current revenue, margins, management, products, segment mix, guidance, market share or capital allocation against the latest 10-K, 10-Q, 8-K, proxy statement, earnings release or official investor-relations material before relying on it.